GENE ONLINE|News &
Opinion
Blog

2026-04-07|

Victory Marine Holdings Corp Launches GUTSI Functional Beverage Platform with Patented Mineral Formulations

by GOAI
Share To

Victory Marine Holdings Corp (OTC: VMHG) has announced the launch of GUTSI™, a multi-category functional beverage platform. The new product line is built on patented mineral formulations and aims to address various consumer needs within the functional beverage market. The company revealed this development as part of its ongoing efforts to expand its portfolio and enter new market segments.

According to information provided, GUTSI™ incorporates unique mineral-based formulations designed for multiple applications across different beverage categories. Victory Marine Holdings Corp stated that the platform will cater to diverse consumer preferences, offering products that align with health-conscious trends in the industry. The announcement marks a strategic move by the company into the growing functional beverage sector, which has seen increasing demand for innovative solutions tailored to wellness and lifestyle needs.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: April 7, 2026

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Author
Related Post
LATEST
[Illustrations] The Diversity Deficit in Oncology Trials: When Enrollment Logic No Longer Reflects Real-World Patients
2026-04-16
Japanese Researchers Identify Stem Cell Dynamics in Vocal Fold Tissue Maintenance and Repair
2026-04-16
Study Identifies Active Role of Skin Cells in Rabies Virus Replication and Transmission
2026-04-16
Contractor Fatality Halts Operations at ATEX Resources’ Valeriano Project in Chile
2026-04-15
Dual Inhibition of xCT and GGCT Induces Ferroptosis in Glioblastoma Cells
2026-04-15
Researchers Develop Method to Convert Ketones into Saturated Heterocycles for Pharmaceutical Applications
2026-04-15
Naturally Occurring Compounds Luteolin, Naringenin, and Scutellarin Identified as Potential Inhibitors of Breast Cancer-Linked Enzymes HDAC4 and HDAC8
2026-04-15
Scroll to Top